This message contains images. If you don't see images, click here to view.
Advertise in this news brief.




Text Version    RSS    Subscribe    Unsubscribe    Archive    Media Kit           July 23, 2014

Home     About SGO    Education    Membership    Clinical Practice    Public Policy    Blog    Partnerships    Store

 

HPV test vs. Pap for gauging cervical cancer risk
HealthDay News via WebMD
A new study involving data on more than 1 million women finds the HPV test outperforming the standard Pap test in assessing cervical cancer risk. Researchers at the U.S. National Cancer Institute (NCI) conclude that a negative test for HPV (human papillomavirus) infection is associated with an extremely low risk for cervical cancer and provides greater assurance of low cervical cancer risk than a negative Pap test.
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE  




MORCELLATION


Study finds new cancer risk from hysterectomy device
The Wall Street Journal (Subscription Required)
New research published by a prestigious medical journal estimates that nearly 1 in 370 women undergoing a hysterectomy with a common women's surgical device have a hidden uterine cancer, the largest assessment yet of the risk posed by a tool that is under scrutiny for its potential to spread undetected cancer. The study, published by Columbia University doctors in the Journal of the American Medical Association, sheds new light on the potential hazards of a surgical tool called a power morcellator that is used to remove uterine growths, fibroids, in laparoscopic surgery. It also found that the device might spread a wider range of cancers than previously believed.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


HPV


HPV persists significantly longer in African-American women
Healio
The time it took for black women to clear a high-risk HPV infection was nearly double that of white women, according to a study published in the Journal of Infectious Diseases. Researchers conducted a prospective longitudinal study by recruiting women at a college student health center. The study included 113 black women and 326 white women who visited the clinic twice a year for HPV testing and Pap smears. Within the cohort, there were 2,121 study visits and 906 (42.7 percent) were positive for HPV. White women were HPV positive on 40 percent of the visits, but black women were positive on 51 percent of the visits.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Advertisement
PRODUCT SHOWCASE
  ChemoFx Improves Ovarian Cancer Outcomes
ChemoFx® provides invaluable information to physicians choosing from 20+ equivalent treatment recommendations without prior knowledge of how individual patients may respond. ChemoFx determines platinum resistance in primary ovarian cancer and demonstrates longer overall survival by 14 months in recurrent ovarian cancer, making it instrumental in improving patient outcomes.
 


OVARIAN CANCER


The importance of reducing patients' symptom burden in cancer
Medscape (Free Login Required)
Dr. Maurie Markman discusses a paper that recently appeared in the International Journal of Gynecological Cancer, "Symptom Burden and Outcomes of Patients With Platinum Resistant/Refractory Recurrent Ovarian Cancer: A Reality Check: Results of Stage 1 of the Gynecologic Cancer Intergroup Symptom Benefit Study."
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


  FEATURED COMPANIES
Work for the best
We are seeking a gyn-oncologist to join our growing health system in Springfield, Mo. Our clinic has on-site lab and radiology services, access to a da Vinci® surgical robot and a strong support staff. For more information about this opportunity at our physician owned and operated clinic, call 1-800-869-4201. MORE
Exceptional Care, Close to Home

21st Century Oncology – the nation’s largest cancer treatment network and global leader in cancer care – providing integrated clinical teams treating patients collaboratively to improve outcomes.
MORE


IMAGING


Self-assembling nanoparticle could improve MRI scanning for cancer diagnosis
(e) Science News
Scientists have designed a new self-assembling nanoparticle that targets tumors, to help doctors diagnose cancer earlier. The new nanoparticle, developed by researchers at Imperial College London, boosts the effectiveness of magnetic resonance imaging (MRI) scanning by specifically seeking out receptors that are found in cancerous cells. The nanoparticle is coated with a special protein, which looks for specific signals given off by tumors, and when it finds a tumor it begins to interact with the cancerous cells. This interaction strips off the protein coating, causing the nanoparticle to self-assemble into a much larger particle so that it is more visible on the scan.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


BREAST CANCER


Breast cancer drug has a surprising new application, study finds
TIME
An early study published in Clinical Cancer Research shows that gel-based tamoxifen may be as effective as the oral drug, and have fewer side effects. Dr. Seema Khan, professor of surgery at Northwestern University Feinberg School of Medicine, reports that putting the drug in a gel, and applying it directly to the breast tissue, where it needs to work, may have merit.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE




RESEARCH


Structure of protein vital to cancer development is mapped
Medical News Today
A major breakthrough has been made by scientists who have successfully managed to map out the structure of a complicated protein that is regarded to be one of the most important in cell division. This knowledge could be used in the future in the development of cancer drugs.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE
 



Women's Cancer News
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Jessica Taylor, Senior Medical Editor, 202-684-7169  
Contribute news


Inclusion of advertisements does not constitute SGO endorsement of company products or services.

Be sure to add us to your address book or safe sender list so our emails get to your inbox. Learn how.

This edition of the Women's Cancer News was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!

Recent issues

July 16, 2014
July 9, 2014
July 2, 2014
June 18, 2014






7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063